Literature DB >> 25106848

Overexpression of recombinant infectious bursal disease virus (IBDV) capsid protein VP2 in the middle silk gland of transgenic silkworm.

Hanfu Xu1, Lin Yuan, Feng Wang, Yuancheng Wang, Riyuan Wang, Chunnuan Song, Qingyou Xia, Ping Zhao.   

Abstract

Infectious bursal disease virus (IBDV) is the causative agent of a highly contagious disease affecting young chickens and causes serious economic losses to the poultry industry worldwide. Development of subunit vaccine using its major caspid protein, VP2, is one of the promising strategies to protect against IBDV. This study aim to test the feasibility of using silkworm to produce recombinant VP2 protein (rVP2) derived from a very virulent strain of IBDV (vvIBDV). A total of 16 transgenic silkworm lines harboring a codon-optimized VP2 gene driven by the sericin1 promoter were generated and analyzed. The results showed that the rVP2 was synthesized in the middle silk gland of all lines and secreted into their cocoons. The content of rVP2 in the cocoon of each line was ranged from 0.07 to 16.10 % of the total soluble proteins. The rVP2 was purified from 30 g cocoon powders with a yield of 3.33 mg and a purity >90 %. Further analysis indicated that the rVP2 was able to tolerate high temperatures up to 80 °C, and exhibited specific immunogenic activity in mice. To our knowledge, this is the first report of overexpressing rVP2 in the middle silk gland of transgenic silkworm, which demonstrates the capability of silkworm as an efficient tool to produce recombinant immunogens for use in new vaccines against animal diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25106848     DOI: 10.1007/s11248-014-9827-7

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  26 in total

1.  Identification and pathogenicity of a natural reassortant between a very virulent serotype 1 infectious bursal disease virus (IBDV) and a serotype 2 IBDV.

Authors:  Daral J Jackwood; Susan E Sommer-Wagner; Beate M Crossley; Simone T Stoute; Peter R Woolcock; Bruce R Charlton
Journal:  Virology       Date:  2011-09-28       Impact factor: 3.616

2.  An optimized sericin-1 expression system for mass-producing recombinant proteins in the middle silk glands of transgenic silkworms.

Authors:  Feng Wang; Hanfu Xu; Lin Yuan; Sanyuan Ma; Yuancheng Wang; Xiaoli Duan; Jianping Duan; Zhonghuai Xiang; Qingyou Xia
Journal:  Transgenic Res       Date:  2013-02-23       Impact factor: 2.788

3.  Germline transformation of the silkworm Bombyx mori L. using a piggyBac transposon-derived vector.

Authors:  T Tamura; C Thibert; C Royer; T Kanda; E Abraham; M Kamba; N Komoto; J L Thomas; B Mauchamp; G Chavancy; P Shirk; M Fraser; J C Prudhomme; P Couble; T Toshiki; T Chantal; R Corinne; K Toshio; A Eappen; K Mari; K Natuo; T Jean-Luc; M Bernard; C Gérard; S Paul; F Malcolm; P Jean-Claude; C Pierre
Journal:  Nat Biotechnol       Date:  2000-01       Impact factor: 54.908

4.  Development of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.

Authors:  Jun Rong; Taipin Cheng; Xiaona Liu; Taozhen Jiang; Hong Gu; Guolin Zou
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 5.  Research on infectious bursal disease--the past, the present and the future.

Authors:  Hermann Müller; Md Rafiqul Islam; Rüdiger Raue
Journal:  Vet Microbiol       Date:  2003-12-02       Impact factor: 3.293

6.  Homologous recombination is apparent in infectious bursal disease virus.

Authors:  Cheng-Qiang He; Le-Yuan Ma; Dong Wang; Guo-Rong Li; Nai-Zheng Ding
Journal:  Virology       Date:  2008-12-06       Impact factor: 3.616

7.  Production of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons.

Authors:  Masashi Iizuka; Shingo Ogawa; Atsushi Takeuchi; Shinichi Nakakita; Yuhki Kubo; Yoshitaka Miyawaki; Jun Hirabayashi; Masahiro Tomita
Journal:  FEBS J       Date:  2009-09-09       Impact factor: 5.542

8.  Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens.

Authors:  Jacob Pitcovski; Bezalel Gutter; Gilad Gallili; Martin Goldway; Beny Perelman; Gideon Gross; Simha Krispel; Marisa Barbakov; Amnon Michael
Journal:  Vaccine       Date:  2003-12-01       Impact factor: 3.641

9.  Structure-dependent efficacy of infectious bursal disease virus (IBDV) recombinant vaccines.

Authors:  Jorge L Martinez-Torrecuadrada; Narciís Saubi; Albert Pagès-Manté; José R Castón; Enric Espuña; J Ignacio Casal
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

10.  Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.

Authors:  Marina Arnold; Vijay Durairaj; Egbert Mundt; Katja Schulze; Karin D Breunig; Sven-Erik Behrens
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

View more
  4 in total

1.  Expression and characterization of recombinant human VEGF165 in the middle silk gland of transgenic silkworms.

Authors:  Tianyang Zhang; Rongpeng Liu; Qin Luo; Dawei Qu; Tao Chen; Ou Yao; Hanfu Xu
Journal:  Transgenic Res       Date:  2019-09-20       Impact factor: 2.788

2.  High yield exogenous protein HPL production in the Bombyx mori silk gland provides novel insight into recombinant expression systems.

Authors:  Huan Wang; Lu Wang; Yulong Wang; Hui Tao; Weimin Yin; Yanghu SiMa; Yujun Wang; Shiqing Xu
Journal:  Sci Rep       Date:  2015-09-15       Impact factor: 4.379

3.  Effects of Osiris9a on Silk Properties in Bombyx mori Determined by Transgenic Overexpression.

Authors:  Tingcai Cheng; Xia Zhang; Zhangchuan Peng; Yinfeng Fan; Lin Zhang; Chun Liu
Journal:  Int J Mol Sci       Date:  2020-03-10       Impact factor: 5.923

4.  A Targeted In-Fusion Expression System for Recombinant Protein Production in Bombyx mori.

Authors:  Zhiqian Li; Lang You; Qichao Zhang; Ye Yu; Anjiang Tan
Journal:  Front Genet       Date:  2022-01-04       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.